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Summary The role of glutathione (GSH) and GSH-S-transferase (GST) activity in modulating the cytotox-
icity of four platinum drugs and melphalan was evaluated in eight human ovarian carcinoma cell lines. The
cell lines were established from solid and ascitic tumours from pretreated and untreated patients, and showed
a wide spectrum of sensitivity to several platinum II and platinum IV drugs; cisplatin, carboplatin, CHIP and
tetraplatin. Intracellular glutathione concentration measured in the cell lines showed a significant (P = <0.05)
correlation with IC5o values for cisplatin (r = 0.91), carboplatin (r = 0.87) and CHIP (r = 0.88). The correlation
between GSH levels and IC50 values for melphalan (r = 0.76) or tetraplatin (r = 0.60) was not as significant.
GST activity showed no correlation with IC50 values, for the four platinum drugs. To determine the
significance of the elevated GSH concentration in the refractory cell lines, the effect of D,L-buthionine-S,
R-sulfoximine (BSO) mediated GSH depletion on platinum drug cytotoxicity was examined in one of the most
sensitive (CHI) and two of the least sensitive (relatively resistant; SKOV-3, HX/62) cell lines. Comparison was
made with the effect of GSH depletion on melphalan cytotoxicity in these three lines. These lines were
differentially sensitive to BSO, with the two most platinum drug resistant lines being more tolerant to BSO
than the sensitive CHI line. Depletion of cellular GSH, ranging between 61 and 88%, had a differential effect
on the sensitivity to PtII vs PtIV drus in the three cell lines: cytotoxicity of the PtIV drugs, tetraplatin and
CHIP, was substantially enhanced in both the resistant and sensitive cell lines; in contrast, the cytotoxicity of
the PtII drugs, cisplatin and carboplatin, was only significantly increased in one of the two relatively resistant
lines (SKOV-3) and in the sensitive (CHI) line after GSH depletion. Moreover the dose modification factor
(DMF) for the PtII agents were lower than those for PtIV agents in the three cell lines. The dose modification
factor for tetraplatin after BSO treatment was similar to that observed for melphalan in all three cell lines. In
the SKOV-3 cell line extending the BSO pretreatment period to 48 h from 24 h marginally reduced the
cytotoxicity of cisplatin, whereas the cytotoxicity of the other three drugs remained similar to that observed
after 24 h BSO pretreatment. In contrast, extending the BSO treatment to 24 h after drug exposure potentiated
the cytotoxicity of cisplatin, CHIP and tetraplatin. The significance of these results in relation to the role of
GSH in the mechanism of action of PtII and PtIV drugs is discussed.
Cisplatin, and the markedly less nephrotoxic second genera-
tion analogue carboplatin, are exceptionally useful anticancer
drugs particularly in the treatment of ovarian and testicular
cancers (Calvert et al., 1985; Peckham et al., 1985; Wiltshaw
& Carr, 1974). However, their efficacy is often compromised
by the development of resistance after an initial response.
Furthermore a number of tumours are unresponsive (intrin-
sically resistant) to these drugs. Clearly there is a need to
develop a new generation of more clinically effective plat-
inum-based drugs and/or to derive methods for modulating
the sensitivity of tumours to the currently available drugs. To
address these issues we have developed a range of human
ovarian carcinoma cell lines and related xenografts, whose
reponse to established platinum drugs reflects that seen
clinically (Hills et al., 1989; Harrap et al., 1990). The
biochemical mechanisms underlying platinum drug sensi-
tivity/resistance in these models are being characterised.
Several mechanisms have been postulated to be involved in
platinum drug resistance in tumour cells, including decreased
drug accumulation, increased inactivation through interac-
tion with cellular thiols, reduced platinum-DNA adduct for-
mation and enhanced repair of DNA lesions (for review see
De Graeff et al., 1988; Eastman & Richon, 1986; Andrews &
Howell, 1990).
Glutathione (GSH), the major intracellular non-protein
thiol, plays an important role in a number of cellular func-
tions, including enzyme activity, membrane transport, DNA
synthesis and inactivation of xenobiotics and reactive inter-
mediates (Meister & Anderson, 1983). GSH and GSH-depen-
dent enzymes are known to reduce the cytotoxic activity and
hence cause resistance to alkylating agents and several other
therapeutic agents (Arrick & Nathan, 1984; Hamilton et al.,
1989). Platinum is known to react avidly with sulphur
ligands, hence elevated cellular GSH may reduce the cytotox-
icities of platinum drugs. However, the evidence for the
involvement of GSH and its dependent enzymes in platinum-
drug resistance still remains equivocal. Both elevated and
unaltered cellular GSH levels have been reported in murine
and human cells, including ovarian carcinoma cells with
acquired resistance to cisplatin (Andrews et al., 1985; Hamil-
ton et al., 1985; Lewis et al., 1988; Richon et al., 1987;
Teicher et al., 1987). Moreover, reduction of cellular GSH by
D,L-buthionine-S, R-sulfoximine (BSO) pretreatment has
had variable effects on cisplatin sensitivity in resistant cells
(Andrews et al., 1985, 1988; Hamilton et al., 1985). The role
of GSH in modulating PtIV drug cytotoxicity has not been
investigated extensively.
The present report describes our investigations into the
role of GSH in modulating the cytotoxicity of platinum
drugs in eight human ovarian carcinoma cell lines, establish-
ed from solid and ascites tumours from pretreated and un-
treated patients. Levels of GSH and glutathione-S-transferase
activity were determined in these cell lines and compared
with the cytotoxic activity of several platinum II and IV
chemotherapeutic agents: cisplatin [cis-diamminedichloroplat-
inum(II)], carboplatin [cis-diamminecyclobutane-l,l-dicarb-
oxylatoplatinum(II)], CHIP (iproplatin) [cis-dichloro-bis-iso-
propylaminetranshydroxyplatinum(IV)] and tetraplatin [d,l-
trans-tetrachloro-1,2-diaminocyclohexaneplatinum (IV) ]. We
have also evaluated, in one sensitive and two relatively resis-
tant cell lines, the effect of BSO-mediated depletion of cellu-
lar GSH on the cytotoxicity of these four platinum drugs and
compared this with the effects on melphalan (L-phenylalanine
mustard) cytotoxicity, since the latter has been reported to be
markedly enhanced after GSH depletion (Hamilton et al.,
1989).
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Materials and methods sodium hydroxide. The GSH content was expressed as nmol
per 106 cells or per mg protein.
Chemicals
Glutathione reductase (type IV bakers' yeast), GSH, 5,5'-
dithiobis-2- (nitrobenzoic acid) (DTNB), D,L-buthionine-S,
R-sulfoximine and 5-sulfosalicylic acid were purchased from
Sigma Chemicals UK Ltd. l-Chloro-2,4-dinitrobenzene
(CDNB) was obtained from Aldrich Chemical Co Ltd,
Dorset. Cisplatin, carboplatin and CHIP were obtained from
the Johnson Matthey Technology Centre. Tetraplatin was a
gift from Dr M. Wolpert-Defilippes (NCI, Bethesda, MD,
USA).
Cell lines
Eight human ovarian carcinoma cell lines were used in this
study. Six (SKOV-3, HX/62, PXN/94, OVCAR-3, CHI and
41M) have been described in detail previously (Hills et al.,
1989). The new lines, LK1 and LK2, were established from
ascitic fluid using methods as described previously (Hills et
al., 1989). The patient's pre-biopsy treatment and response
were as follows: LKI, carboplatin with partial response and
trimelamol with stable disease; LK2, carboplatin with no
response and cisplatin with no response.
Drug exposure and cytotoxicity assay
Cells were grown in Dulbecco's Modified Eagles Medium
(DMEM) plus 10% foetal calf serum, 50jig ml-' gentamicin,
2.5jLg m1' amphotericin B, 2 mM glutamine, 10 sg ml-'
insulin and 0.5 gLg ml-' hydrocortisone. Cells were periodic-
ally checked and found to be free ofmycoplasma and used in
these studies from passage 25 to 50. The sensitivity of each
cell line to the four platinum agents (cisplatin, carboplatin,
CHIP and tetraplatin) was examined as described previously
(Hills et al., 1989) with the following modifications: single
cells harvested by trypsinisation (0.02% EDTA/0.05% tryp-
sin) were plated at between 5 x I03 and 1 x 104 in 96-well
microtitre plates. After allowing attachment overnight, cells
were exposed to agents in quadruplicate wells for a total of
either 2 or 96 h. At the end of the 2 h period fresh medium
was applied and the cells were grown for a further 96 h.
Cytotoxicity was then assessed by staining basic amino acids
with sulforhodamine B (SRB), as modified from Skehan et
al. (1989). Briefly, the medium was aspirated and the cells
exposed to ice-cold 10% w/v trichloroacetic acid (TCA) for
30 min. For cell lines prone to detachment (CHI, LK2) from
the wells, a 5 min bath in ice-cold methanol was then
included. Cells were then washed five times with tap water,
held in 100IlI 0.4% SRB (Sigma Chemicals) in 1% acetic
acid for 10 to 15 min and washed five times with 1% acetic
acid. After air-drying overnight, the protein bound SRB was
solubilised with 1001il of 10mM Tris base and the plates
read at 540 nm using a plate reader (Titertek Multiscan
MCC/340, Flow Laboratories). By comparing treated with
untreated control wells, IC50 values were then determined
using a computer software package (Titersoft II, Flow
Laboratories).
GSH assay
Cellular GSH content was determined in cells grown under
conditions identical to those used for cytotoxicity assay. For
adequate cell numbers, however, 0.5- 1.0 x 106 cells were
plated as monolayers in T25 flasks (Flow Laboratories).
After a 24 h attachment period the medium was aspirated
and the cells were washed twice in 10 ml of cold phosphate
buffered saline (PBS), pH 7.4. Cellular GSH was then ex-
tracted according to Russo et al. (1986), by addition of
2.0 ml of cold 0.6% sulphosalicylic acid followed by 10 min
incubation at 4°C with occasional shaking. Total GSH in the
extract was assayed by the method of Griffiths (1980). The
protein content of the extracted cells was analysed according
to Lowry et al. (1951) after solubilisation in 2.0 ml of 1.0 N
Effect ofBSO exposure on intracellular GSH concentration
Preliminary studies were performed to establish the effect of
BSO treatment on intracellular GSH content in one sensitive
(CHI) and two resistant (SKOV-3 and HX/62) cell lines.
Single cells (5 x 105) were plated in T25 flasks and divided
into four groups of three flasks. After a 24 h attachment
period, the medium was aspirated and replaced with medium
containing BSO (2 groups) or vehicle (2 control groups). The
BSO concentration ranged from 12.5jLM to 50giM, depending
on the cell line investigated. One control and one BSO
treated group were incubated for 24 h and the remainder
were incubated for 48 h. At the end of these periods one flask
from each group was used for cell count and the other two
were used for GSH determination. Cellular GSH was ex-
tracted and analysed as described above. However, GSH was
extracted using 1.0 ml of 0.6% sulphosalicylic acid in order
to concentrate the extracts. Preliminary experiments had
shown that maximum extraction was achieved with this
volume. Cell growth and viability 96 h after exposure to BSO
at each concentration and time period was also examined in
a separate experiment. The BSO concentration and time of
exposure which did not alter cell growth and viability were
subsequently used to examine the effect of cellular GSH
depletion on platinum-drug sensitivity. These values were as
follows: 50tLM BSO, 24 h exposure for the two resistant lines,
SKOV-3 and HX/62 and 12.5 giM BSO, 24 h exposure for the
sensitive line, CHI.
Effect ofcellular GSH depletion on the cytotoxicity of
platinum drugs
The effect of glutathione depletion on cellular response to
platinum drugs was assessed in three cell lines, SKOV-3,
HX/62 and CH1 as described above with the following modi-
fication. Cells seeded in 96-well microtitre plates were
allowed to attach overnight and then incubated in a medium
containing an appropriate concentration of BSO or vehicle
for a further 24 h. This was followed by a 2 h incubation in
medium containing appropriate concentrations of platinum
drug and BSO or vehicle. At the end of this period fresh
medium was applied and cell survival assessed 96 h later as
described above.
Glutathione-S-transferase (GST) assay
Following a 24 h attachment period in T25 flasks, cells
(3-5 x 106) in log phase growth were washed twice with
20 ml of cold PBS, scraped and harvested using 3.0 ml of
PBS. The cell suspension was sonicated (Polytron sonicator,
MSE, Fisons Ltd) using 3 x 5 s pulses at 0.75 max power
with 20 s cooling period at 4°C between each pulse. The cell
sonicate was centrifuged at 11,000g for 25 min at 4°C and
the supernatant analysed for GST activity using 1 mM
CDNB as the substrate (Habig et al., 1974).
Results
Cytotoxicity ofplatinum drugs
Cytotoxicity of cisplatin, carboplatin, CHIP and tetraplatin
in the eight human ovarian carcinoma cell lines is shown in
Figure 1. The cell lines exhibited a wide range of sensitivity
to the four platinum compounds. The HX/62 and SKOV-3
cells lines were generally the most resistant, while the PXN/
94 cell line showed differential sensitivity to the four
platinum agents, being very sensitive to tetraplatin relative to
the other three drugs.GLUTATHIONE AND CYTOTOXICITY OF PLATINUM DRUGS 217
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Figure 1 Sensitivity of the eight human ovarian carcinoma cell
lines to the four platinum drugs. ICn values (mean +s.d.,
n = 4-7) were assessed by sulforhodamine B assay using a 96 h
continuous drug exposure as outlined in Materials and methods.
Relationship between GSH concentration andIC50 values of
platinum drugs and melphalan
The concentration of GSH and GST activity in the eight
ovarian carcinoma cell lines is shown in Table I. A significant
correlation was observed between intracellular GSH concen-
tration (expressed as either nmol per 106 cells or per mg
protein) and ICs values obtained after 2 or 96 h continuous
exposure to cisplatin (r = 0.91), carboplatin (r = 0.87) and
CHIP (r = 0.88) in these cell lines (Table II and Figure
2a-c). The GSH content did not correlate with sensitivity to
tetraplatin when all eight cell lines were considered (r = 0.13).
However, without the inclusion of the PXN/94 cell line,
which is differentially sensitivity to tetraplatin, and which
also contains high GSH concentration the correlation (r =
0.60) was improved (Table II and Figure 2d). The mechan-
isms involved in the exquisite sensitivity of the PXN/94 cell
line to tetraplatin is currently being investigated.
The ICs values for melphalan also showed a positive
correlation (r = 0.77) with cellular GSH content in six of the
cell lines. However, statistical significance was not achieved
(Table II).
The effect ofBSO on cellular GSH concentration
Treatment of SKOV-3 cells with 25 gM BSO reduced the
GSH levels by 70% and 83% at 24 h and 48 h, respectively.
Exposure to 500lM BSO reduced the GSH concentration by
88% and 97% respectively, at the two time points (Figure
3a). Furthermore no growth delay or loss of viabilty were
observed 96 h after exposure to 50 SlM BSO up to 48 h. In
another resistant cell line, HX/62, treatment with 50 pM BSO
for 24h, which reduced cellular GSH content by 61% also
had no effect on cell growth and viability (Figure 3b). How-
ever, exposure to 50 jLM BSO for 48 h did partially reduce the
growth rate of these cells. In contrast, in the CHI cell line,
which is one of the most sensitive to platinum drugs,
exposure to BSO was less well tolerated than in the resistant
cell lines. Exposure of CH1 cells to 25 4M BSO for 24 h had
an adverse effect on cell viability, although exposure to
12.5ILM BSO for 24h, which reduced cellular GSH by 81%,
was well tolerated (Figure 3c).
Effect ofBSO pretreatment on cytotoxicity ofplatinum-drugs
andmelphalan
Reduction of cellular GSH by 88% in the SKOV-3 cells
significantly (P<0.01) potentiated the cytotoxicity of all four
Pt drugs. However, the dose modification factor (DMF) for
the PtIV drugs, CHIP and tetraplatin was greater than for
the PtII drugs, cisplatin and carboplatin (Table III). In the
HX/62 cell line a 61% reduction in its GSH content did not
potentiate the cytotoxicity of PtII drugs, whereas the sen-
sitivity to PtIV drugs was significantly enhanced (Table III).
In both SKOV-3 and HX/62 cell lines the DMF for tetra-
Table I GSH levels and GST-activity in the eight human ovarian
carcinoma cell lines
GSH concentrationa GSTspecific activityc
nmol 10-6 nmolmg-1 nmolproduct min- mg-
Cell line cells protein nb protein
HX/62 59.8± 8.7 47.0± 7.8 8 109±21
SKOV-3 50.2±6.0 72.3± 16.0 8 150±14
PXN/94 60.2±18.1 59.3± 18.8 11 145±22
OVCAR-3 20.4± 7.6 26.4±3.4 9 199±25
41M 8.8±0.6 18.2±2.5 10 135± 18
LKI 13.3±0.4 31.8± 1.2 3 115
LK2 19.0±0.3 31.1±0.3 3 155
CHI 19.4±3.0 24.2±3.6 10 122±6
-~~~~~~~~~ 'Values are mean±s.d. bNumber of determinations on at least four
separate cultures except for LKI and LK2 cell lines, where all the
samples were from one culture. CGST activity mean±s.d. (n = four
separate cultures, except for LKI and LK2 cell lines where n = 2).
Table II Correlation coefficients (r) between intracellular GSH con-
tent and IC50 values for the fourplatinum drugs and melphalan ineight
human ovarian carcinoma cell lines
Correlation coefficient (r)a
GSH nmol J0-6 cells with GSH nmolmg-'protein with
Drug 2 h IC50 96 h IC50 2 h Ic5O 96 h IC50
Cisplatin 0.83 0.91 0.69 0.78
p <0.03 <0.005 NS <0.03
Carboplatin 0.85 0.87 0.69 0.75
P <0.01 <0.05 NS <0.05
CHIP 0.87 0.88 0.65 0.73
P <0.01 <0.005 NS <0.05
Tetraplatin 0.18 (0.69)b 0.13 (0.60) 0.39 (0.85) 0.34 (0.77)
p NS (NS) NS (NS) NS (< 0.03) NS (<0.05)
Melphalanc 0.76 0.71
p NS (NS)
aCorrelation coefficients were determined from linear regression
analysis. bFigure in parentheses represent value calculated without the
inclusion of the PXN/94 cell line. CCorrelation coefficient determined
using 96 h IC50 values from six cell lines; cytotoxicities ofmelphalan in
the LK1 and LK2 cell lines were not determined.
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Figure 2 Correlation between intracellular glutathione content
and sensitivity of the ovarian cell lines to four platinum drugs.
ICn values were determined using a 96 h continuous drug expo-
sure assay as outlined in Materials and methods. In panels a and
b points for two lines, CHI and LK2, overlap. In panel d, dotted
line excludes PXN/94 cell line data. s.d. (bars) was smaller than
the symbol size where not indicated.
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Figure 3 Effect of BSO treatment time on intracellular GSH
concentration in a, SKOV-3, b, HX/62 and c CHI cell lines. GSH
levels were determined as stated in Materials and methods. Open
bars represent control cells and dashed bars represent BSO-
treated cells. The CHI cells were treated with 12.5JuM BSO and
the SKOV-3 and HX/62 cells were treated with 50 pM BSO.
Values are mean±s.d. where n = 4 except for HX/62 48 h time
point where n = 2.
platin was similar to that observed for melphalan. An 81%
depletion of intracellular GSH in the sensitive CHI cells
caused a significant potentiation of PtII drug cytotoxicity.
Moreover, the DMFs for these drugs were greater than those
observed in the resistant lines (Table III). Tetraplatin and
melphalan cytotoxicity in the CHl cells was enhanced to a
similar extent as that seen in the resistant cells after GSH
depletion (Table III). In preliminary experiments with
SKOV-3 cells we observed that extending the BSO pretreat-
ment period from 24 h to 48 h before exposure to the drugs
marginally reduced the DMF for cisplatin from 1.25-1.33
(range, n = 2) to 0.72-0.92 (range, n = 2), whereas the DMF
for carboplatin, CHIP and tetraplatin remained similar in the
two groups. In addition, exposure of the SKOV-3 cells to
50tLM BSO for 24 h prior to and following drug treatment
increased the DMF for cisplatin, CHIP and tetraplatin rela-
tive to that observed after 24 h BSO pretreatment only
(Table IV). In contrast, the DMF for carboplatin in these
two treatment groups was similar.
Intracellular GST concentrations
The GST activity in the eight cell lines, measured using
1-chloro-2, 4-dinitrobenzene as the substrate, are shown in
Table I. No correlation was observed between GST activity
and IC50 values for any of the four platinum drugs examined.
Discussion
In this study we have measured GSH levels in eight human
ovarian carcinoma cell lines established from patients who
were either untreated or pretreated with platinum and non-
platinum-containing regimens. This panel of lines had a
range of sensitivity to platinum drugs similar to that
observed in the clinic (Hills et al., 1989); with the SKOV-3
and HX/62 cells lines being the most refractory (relatively
resistant), and the CHI line being one of the most sensitive.
Cellular GSH was determined in cells grown under condi-
tions reflecting those used for drug cytotoxicity assay,
because GSH and GSH-dependent enzyme levels vary with
time after plating in both murine and human cells (Batist et
al., 1986; Post et al., 1983). Indeed, in agreement with these
reports, our own data showed that GSH levels per 106 cells
were higher at 24 h than at 48 h after plating. The GSH
concentrations in the eight ovarian cell lines showed a strong
inverse correlation with sensitivity to both PtII and PtIV
group drugs. As far as we are aware this is the first time such
a correlation has been observed in a group of human ovarian
carcinoma cells with such a wide (approximately 100-fold)
range of sensitivity to platinum drugs (Hills et al., 1989).
Recently Hosking et al. (1990) have reported a correlation
between cisplatin sensitivity in various cell types and their
GSH content. Elevated GSH levels in human cells with
acquired resistance to cisplatin have also been reported
(Hamilton et al., 1985; Lewis et al., 1988; Teicher et al.,
1987). In one study, Lewis et al. (1988) found that, relative to
a sensitive ovarian cell line (PEOI), GSH and GSH-
dependent enzymes were higher in a resistant (PE04) line
established from the same patient after relapse on cisplatin-
containing therapy.
To establish whether the elevated GSH levels played a role
in the mechanism of resistance to platinum drugs we examin-
ed the effect of BSO- mediated GSH depletion on the cyto-
toxicity of these drugs in one sensitive (CHI) and two
relatively resistant (SKOV-3, HX/62) cell lines. The cell lines
were found to be differentially sensitive to BSO exposure,
with the most sensitive being the CHI cell line, followed by
HX/62 and then SKOV-3; hence the platinum resistant cells
were more tolerant to BSO than the platinum sensitive cells.
Depletion of cellular GSH had a differential effect on the
cytotoxicity of PtII vs PtIV complexes in these three cell
lines. The cytotoxicity of PtIV drugs was enhanced signi-
ficantly (P<0.05) in all three cell lines whereas the cytotox-
icity of the PtII drugs was only significantly enhanced in one
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TableIII Dose modification factors for platinum drugs and melphalan in human ovarian carcinoma cell
lines following BSO-mediated GSH reduction
DMF
Cell line Cisplatin Carboplatin CHIP Tetraplatin Melphalan
SKOV-3 1.34±0.26 1.16±0.11 1.61±0.18 2.31 ±0.91 2.74±0.21
n 11 10 10 10 3
Pt <0.01 <0.01 <0.05 <0.01 <0.01
HX/62 1.26±0.29 0.91±0.15 1.67±0.04 2.89± 1.35 3.04± 1.05
n 4 4 4 4 4
P NS NS <0.01 <0.05 <0.05
CHI 1.49±0.50 1.52±0.38 1.52±0.39 2.55±2.09 2.75± 1.43
n 7 6 5 6 5
P <0.05 <0.05 <0.05 <0.05 <0.01
*DMF = (IC50 in the absence of BSO)/(IC50 for drug after BSO pretreatment), values are mean± s.d.
Cellular GSH in the SKOV-3, HX/62 and CHI cell lines was depleted by 88, 61 and 81%, respectively.
tStatisticaly significance was tested by paired t-test.
Table IV Effect of BSO treatment period on dose modification factors for platinum
drugs in the SKOV-3 cell line
BSO treatment" DMP
period Cisplatin Carboplatin CHIP Tetraplatin
24 h pre-drug 1.55 1.28 1.41 1.75
drug exposure (1.32-1.74) (1.25-1.30) (1.28-1.60) (1.63-1.85)
24 h per- and 1.98 1.32 2.62 2.10
24 h post-drug (1.53-2.24) (1.21-1.38) (2.33-2.95) (1.63-2.40)
exposure
'DMF = (IC50 in the absence of BSO)/(IC50 for drug after BSO treatment). Values
reportedaremean(rangeinparentheses) ofthreeexperiments.'Timeofexposureto50gM
BSO in relation to 2 h drugexposure; BSOwas alsopresent duringexposure to thedrugs.
of the resistant (SKOV-3; P<0.01) and in the sensitive
(CHI; P<0.05) cell line. Moreover, of the four platinum
drugs examined the highest DMF was observed for tetra-
platin followed by CHIP in the three cell lines. Hence BSO
mediated GSH depletion acts as a sensitiser of PtIV drug
action in the sensitive as well as in the relatively resistant
cells. A substantial increase in cytotoxicity of CHIP but not
that of cisplatin or carboplatin in two murine cell lines after
GSH depletion have also been reported (Brock & Smith,
1988). However, Andrews et al. (1985) showed no alteration
in sensitivity to CHIP or PtII drugs after GSH depletion in
human ovarian cell lines with acquired resistance to cisplatin.
These authors subsequently reported (Andrews et al., 1988)
that cisplatin resistance in these cells could be partially
reversed if GSH depletion was maintained after drug treat-
ment by prolonging the exposure to BSO. Maintenance of
BSO exposure during cisplatin treatment also increased drug
cytotoxicity in both sensitive and resistant A2780 ovarian
carcinoma cell lines (Hamilton et al., 1985). Our results also
showed that, in the relatively resistant SKOV-3 cell line,
maintenance of GSH depletion 24 h after drug treatment
increased the DMF for cisplatin, CHIP and tetraplatin rela-
tive to that observed when cells were pretreated with BSO for
24 h only. This increase may be due to inhibition of DNA
repair as well as reduced inactivation of active species as a
result of GSH depletion (Lai et al., 1989).
The fact that the DMF for PtIV drugs were greater than
those for PtII drugs in the relatively resistant cells suggests
that GSH may play a more significant role in the mechanism
of resistance to PtIV than PtII drugs. However, it is possible
that BSO may have interfered with PtII drug action, particu-
larly that of cisplatin, in the two resistant cell lines either
directly or indirectly through a mechanism which counteracts
the beneficial effects of GSH depletion. Evidence to support
this comes from the fact that the DMFs for cisplatin after
24 h BSO exposure in the resistant cells were marginally
higher than those observed after 48 h BSO treatment. In
addition, cisplatin induced nephrotoxicity has been shown to
be augmented by concomitant administration of BSO (Mayer
et al., 1987). The differential sensitisation of the resistant
ovarian cells to PtII and PtIV drugs after BSO pretreatment
may be due to the differences in the rate at which GST
catalyses the reaction of these complexes with GSH. The
relationship between GST activity and platinum drug action
is unclear and both increased and unaltered activity have
been reported in cells with acquired resistance to cisplatin
(Hamilton et al., 1985; Lewis et al., 1988; Wang et al., 1989).
Our own data showed no correlation between total GST
activity and sensitivity to the four platinum drugs. However,
it is possible that a specific isoenzyme may mediate a differ-
ential response, and GST isoenzyme profiles are currently
being investigated in these cell lines. The fact that the DMFs
for tetraplatin and the PtII drugs are different after GSH
depletion is intriguing because the complex entering the
ovarian cells after exposure to tetraplatin is probably 1,2-
diaminocyclohexanedichloroplatinum (II), since tetraplatin is
rapidly reduced to this complex (t1, 5-15 min) in RPMI
tissue culture medium and plasma (Gibbons et al., 1989). Our
own data (unpublished) have also shown a very rapid reduc-
tion of tetraplatin by the ovarian cell culture medium. More-
over, the enhancement of PtIV drug cytotoxicity after GSH
depletion is interesting since it is widely believed that these
drugs are activated by reduction to PtII complexes and that
this process is partially mediated by intracellular GSH
(Cleare, 1977; Eastman, 1987). On this basis GSH depletion
should have antagonised PtIV drug cytotoxicity.
Our data confirm that melphalan cytotoxicity is greatly
enhanced by GSH depletion in both sensitive and resistant
ovarian carcinoma cell lines (Andrews et al., 1985; Green et
al., 1984; Hamilton et al., 1985). Moreover the DMF values
observed for tetraplatin were similar to those observed for
melphalan in the three cell lines examined. If the enhanced
cytotoxicity of tetraplatin and CHIP after GSH depeletion
represents a typical response of PtIV complexes then this
could be of significance in future platinum drug development.
In summary, intracellular GSH but not GST levels showed
a strong inverse correlation with sensitivity to PtII and PtIV
drugs in eight human ovarian carcinoma cell lines. However,
modulation ofplatinum drug cytotoxicity in response to BSO
pretreatment suggests that GSH may play a more significant
role in the mechanism of resistance to PtIV than PtII drugs.
The mechanisms involved in this differential response are
unknown and need to be investigated further along with the
intracellular metabolism of these complexes in order to
evaluate the exact role of GSH and GSH-dependent enzymes
in modulating platinum drug action.220 P. MISTRY et al.
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